These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 8676822

  • 1. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C, Krämer-Guth A, Nauck M, Quaschning T, Pavenstädt H, Schollmeyer P.
    Miner Electrolyte Metab; 1996; 22(1-3):39-46. PubMed ID: 8676822
    [Abstract] [Full Text] [Related]

  • 2. Receptor-mediated uptake of IDL and LDL from nephrotic patients by glomerular epithelial cells.
    Krämer A, Nauck M, Pavenstädt H, Schwedler S, Wieland H, Schollmeyer P, Wanner C.
    Kidney Int; 1993 Dec; 44(6):1341-51. PubMed ID: 8301935
    [Abstract] [Full Text] [Related]

  • 3. Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells.
    Krämer-Guth A, Nauck M, Pavenstädt H, Königer M, Wieland H, Schollmeyer P, Wanner C.
    J Am Soc Nephrol; 1994 Oct; 5(4):1081-90. PubMed ID: 7849247
    [Abstract] [Full Text] [Related]

  • 4. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
    Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H.
    Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
    [Abstract] [Full Text] [Related]

  • 5. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H.
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [Abstract] [Full Text] [Related]

  • 6. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO, Samuelsson O, Alaupovic P.
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Very low density lipoproteins and subclasses of intermediate density lipoproteins in postmenopausal women].
    Berg G, Halperín H, Siseles N, Wikinski R.
    Medicina (B Aires); 1996 Jun; 56(5 Pt 1):479-86. PubMed ID: 9239883
    [Abstract] [Full Text] [Related]

  • 12. High lipid levels in very low density lipoprotein and intermediate density lipoprotein may cause proteinuria and glomerulosclerosis in aging female analbuminemic rats.
    Joles JA, van Goor H, van der Horst ML, van Tol A, Elema JD, Koomans HA.
    Lab Invest; 1995 Dec; 73(6):912-21. PubMed ID: 8558854
    [Abstract] [Full Text] [Related]

  • 13. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.
    Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M.
    N Engl J Med; 1990 Aug 30; 323(9):579-84. PubMed ID: 2381443
    [Abstract] [Full Text] [Related]

  • 14. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2004 Sep 30; 24(9):1703-7. PubMed ID: 15242863
    [Abstract] [Full Text] [Related]

  • 15. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
    Duvillard L, Pont F, Florentin E, Galland-Jos C, Gambert P, Vergès B.
    Eur J Clin Invest; 2000 Aug 30; 30(8):685-94. PubMed ID: 10964160
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dietary cholesterol induced changes in lipid profile in patients with nephrotic syndrome and chronic renal failure.
    Jain PK, Arora RC, Agarwal N, Garg RK, Arora S, Gurbaxani RK, Sharma D.
    J Assoc Physicians India; 1991 Oct 30; 39(10):751-3. PubMed ID: 1816199
    [Abstract] [Full Text] [Related]

  • 18. Lipoprotein profiles in a heterogeneous group of patients with nephrotic syndrome.
    Michaeli J, Bar-On H, Shafrir E.
    Isr J Med Sci; 1981 Nov 30; 17(11):1001-8. PubMed ID: 7319786
    [Abstract] [Full Text] [Related]

  • 19. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC, Watts GF, Barrett PH, O'Neill FH, Thompson GR.
    Obes Res; 2003 Apr 30; 11(4):591-6. PubMed ID: 12690090
    [Abstract] [Full Text] [Related]

  • 20. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI, Schreier L, Elbert A, Berg G, Beresan H, López G, Wikinski R.
    Metabolism; 2003 Jan 30; 52(1):116-21. PubMed ID: 12524671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.